Navigation Links
HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
Date:5/8/2012

FRAMINGHAM, Mass. and SYDNEY, May 8, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that enrollment is complete in ENDURANCE, the Company's pivotal Destination Therapy clinical study to evaluate the use of the HeartWare® Ventricular Assist System in patients with end-stage heart failure.

"Completing enrollment in this, the largest head-to-head ventricular assist device clinical trial to date, is a major achievement and we look forward to following this Destination Therapy patient population to primary endpoint over the next two years," said Doug Godshall, President and Chief Executive Officer.  "We are thankful for the diligence of the investigators and site coordinators at the 50 U.S. hospitals in the ENDURANCE study.  With enrollment of the study complete, we are pleased to report that more than 2,000 end stage heart failure patients globally have received the HeartWare Ventricular Assist System."

ENDURANCE is a randomized, controlled, unblinded, multi-center clinical trial to evaluate the use of the HeartWare Ventricular Assist System as a Destination Therapy in advanced heart failure patients.  The non-inferiority study enrolled 450 patients with end-stage heart failure who have not responded to standard medical management and who are ineligible for cardiac transplantation.  Patients were randomly selected to receive either the HeartWare Ventricular Assist System or, as part of a control group, any alternative LVAD approved by the FDA for Destination Therapy, in a 2:1 ratio.  Each patient receiving the HeartWare Ventricular Assist System or control LVAD will be followed to the primary endpoint at two years, with a subsequent follow-up p
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
4. HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
5. HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
6. HeartWare Schedules Fourth Quarter Conference Call and Webcast
7. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
8. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
9. HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
10. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
11. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... agreement has been reached with the US Food ... a pivotal, Phase 3 clinical trial evaluating its ... cutaneous T-cell lymphoma (CTCL).  SGX301 ...
(Date:9/17/2014)... China , Sept. 17, 2014 Mindray ... been officially released worldwide. The system has been showcased ... Barcelona during 14-17th September, and is scheduled ... Designed to be the most efficient workhorse ... versatile diagnostic tools with a perfectly optimized user experience ...
(Date:9/16/2014)... , 17 settembre 2014 Hologic, ... oggi il lancio in Europa del Tomcat, un ... è una piattaforma multifunzionale completamente automatizzata, progettata per ... inefficienze ed i rischi di errore legati alla ... dello strumento Tomcat di Hologic riduce il carico ...
Breaking Medicine Technology:Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Quality Exams at Your Fingertips 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
... Janam Technologies LLC, a leading ... communicate wirelessly, today announced a new mobile healthcare ... product line with antimicrobial versions of the XM66 and ... provide the healthcare sector with rugged antimicrobial devices ...
... SILVER SPRING, Md., Oct. 14 The U.S. ... that their over-the-counter (OTC) chelation products are unapproved ... violation of federal law to make unproven claims ... chelation products. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Janam Introduces Mobile Healthcare Product Line 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 3FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 4
(Date:9/17/2014)... Kathleen Doheny HealthDay Reporter ... major food and beverage companies have made good on their ... report finds. The companies, acting together through the Healthy ... the market between 2007 and 2012 and 1.5 trillion by ... "The 16 companies collectively met their pledge and exceeded their ...
(Date:9/17/2014)... at Moffitt Cancer Center, including Center Director Thomas A. Sellers, ... discovered 23 new regions of the genome that influence the ... Sept. 14 in Nature Genetics . , Prostate cancer ... 1 in 6 men will be diagnosed with the disease ... A man with one close relative, a brother or father ...
(Date:9/17/2014)... facial paralysis are perceived as being less happy simply ... facial expression, a new study from an Oregon State ... the important role the face plays in everyday communication ... with facial paralysis because of their disability, said Kathleen ... of Liberal Arts at Oregon State University. , "People ...
(Date:9/17/2014)... 2014 Tools4ever, the market ... solutions and Boston Software Systems, leader in ... relationship. Under the agreement, Tools4ever will ... functionality within its identity and password management ... healthcare automation platforms that streamline complex processes ...
(Date:9/17/2014)... Kessler Foundation is the recipient of one of ... Multiple Sclerosis (MS) Alliance. Nancy Chiaravalloti, PhD, ... Research, is principal investigator of the study, which ... in individuals with progressive multiple sclerosis. The Foundation ... the Alliance to investigators in nine countries, with ...
Breaking Medicine News(10 mins):Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2
... Older workers benefit most from a modest health behavior ... personal coaching. University of Illinois at Chicago researchers ... interventions assessing older workers, health behaviors and outcomes. The ... an upcoming issue of the American Journal of Public ...
... April 14 (HealthDay News) -- Trying to make the best of ... cope with losing their jobs, a new United Kingdom study finds. ... with their job loss were able to see the event as ... volunteering and study. They also took a contemplative view of ...
... SEATTLE Everyone knows that eating a low-fat, low-calorie diet ... study led by researchers at Fred Hutchinson Cancer Research Center ... body fat, diet and exercise are most effective when done ... of this randomized trial, led by Anne McTiernan, M.D., Ph.D., ...
... 14, 2011 An enzyme essential for DNA replication and ... exploited as anti-cancer therapy, say researchers at The Scripps Research ... in the April 15, 2011 issue of the journal Cell, ... flap endonucleases, which are essential to the life of a ...
... of Alberta shows that for best results in stable patients ... is the key to the best outcomes. Study co-authors Mark ... Clark, researcher in the Faculty of Nursing, along with fellow ... Public Health, and Ian Paterson in the Faculty of Medicine ...
... During the winter of 2008�, a three-week armed conflict ... named "Operation Cast Lead" resulted in hundreds of rocket ... this time children and their families spent hours and ... Although the psychological effects of children,s health are ...
Cached Medicine News:Health News:Older workers benefit from high-tech, high-touch health promotion 2Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 4Health News:Heart needs work after heart attack: U of A Study challenges the notion that the heart must rest 2Health News:Teachers-based intervention provides stress resistance in war-exposed children 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: